| 1718GCCC-S17 | A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, azacitidine (Aza) and venetoclax (Ven) in newly diagnosed, untreated Acute Myeloid Leukemia (AML) Patients >/= 60 years with NPM1 mutated/FLT3-ITD and FLT3-TKD wild type AML or Mixed Lineage
Leukemia (MLL) Gene Rearrangements | Open |
| 1718GCCC-S6 | A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD Wild Type AML Patients Age >/= 18 years | Open |
| 2035GCCC | 2035GCCC: A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T) | Open |
| 2087GCCC | 2087GCCC: Pegcrisantaspase in combination with venetoclax for treatment of relapsed or refractory acute myeloid leukemia (R/R AML) | Open |
| 2099GCCC | 2099GCCC: A Multicenter Phase II Study of Blinatumomab for Treatment of Adult Patients with Morphologic Relapsed/Refractory or Measurable Residual Disease (MRD) CD19-Positive Mixed Phenotypic Acute Leukemia (MPAL) | Open |
| 2100GCCC | Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant | Open |
| 2103GCCC | 2103GCCC: Phase 1/1b trial of talazoparib and gemtuzumab ozogamicin (GO) in adult patients with relapsed and/or refractory acute myeloid leukemia (I_435819 Roswell Park) | Open |
| 21138GCCC | 21138GCCC: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed Previously Untreated Patients with Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy | Open |
| 2189GCCC | 2189GCCC: A Phase Ib/II Study of APG-2575 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS) | Open |
| 2208GCCC | 2208GCCC:A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study) | Open |